Bradykinesia News and Research

RSS

Phase–amplitude coupling changes may underlie DBS success in parkinsonism

Deep-brain stimulation of the subthalamic nucleus may improve motor symptoms in patients with Parkinson’s disease by reducing excessive cortical phase–amplitude coupling, researchers report in Nature Neuroscience.

14 Apr 2015

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel.

4 Mar 2015

Nonmotor predictors of Parkinson’s dementia revealed

Researchers have identified nonmotor and nondopaminergic motor features that predict incident dementia in patients with Parkinson’s disease.

22 Oct 2014

Brain network measures placebo effects in Parkinson's disease patients

Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation.

19 Jul 2014

Low accuracy of clinical diagnosis for early Parkinson’s disease

About three-quarters of patients suspected to have early Parkinson’s disease eventually prove to have other conditions, a study shows.

3 Jul 2014

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment.

5 Mar 2014

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received another allowance of claims from the U.S. Patent Office. The application covers a system and method of controlling Parkinson's therapy in response to motor symptoms.

5 Feb 2014

Kinesia ProView™ launched to visualize motor symptom severity response to deep brain stimulation (DBS) in Parkinson’s patients

Great Lakes NeuroTechnologies announced today the product launch of Kinesia ProView™ to visualize motor symptom severity response during programming of deep brain stimulation (DBS) for Parkinson’s disease. Kinesia ProView provides a standardized platform to quantitatively assess how symptoms such as tremor, bradykinesia, and dyskinesias change in response to specific DBS settings during outpatient programming procedures.

15 May 2013

Parkinson's-related mutations may also affect vision

The most common genetic cause of Parkinson's is not only responsible for the condition's distinctive movement problems but may also affect vision, according to new research by scientists at the University of York.

16 Feb 2013

Intelligent algorithms for programming deep brain stimulation in Parkinson’s to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies (GLNT) announced today that they are launching a study to determine the feasibility of using intelligent algorithms to assist with programming deep brain stimulation settings for Parkinson’s disease.

22 Jan 2013

Parkinson’s assessment devices from Great Lakes NeuroTechnologies receive TGA approval

Great Lakes NeuroTechnologies announced today that they received TGA approval to market Kinesia technology in Australia. The Kinesia™ product line includes patient-worn motion sensors and a tablet computer to quantitatively assess tremor, bradykinesia, and dyskinesia associated with Parkinson’s disease and in response to treatments.

10 Jan 2013

Bradykinesia is ‘context-specific’ in Parkinson’s

Patients with Parkinson’s disease can make rapid responses to avoid adverse stimuli, but cannot speed up their actions to gain a reward, report UK researchers.

16 Nov 2012

Bradykinesia in Parkinson’s disease: an interview with Dr. Joseph Giuffrida, President of Great Lakes NeuroTechnologies

Currently in the United States, there are over 1.5 million people living with Parkinson's and 50,000 new cases reported each year

30 Aug 2012

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they have received $1.5 million in funding to commercialize a technology for Parkinson’s disease (PD) patients that will better assess motor symptoms in response to new deep brain stimulation (DBS) and pharmaceutical therapies.

8 Aug 2012

Surprise result in caffeine trial for Parkinson’s patients

Caffeine treatment may improve motor symptoms in patients with Parkinson’s disease, research suggests.

7 Aug 2012

Micrographia prevalent in Parkinson’s

Around half of patients with Parkinson’s disease display symptoms of micrographia, a case–control study shows.

19 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Deep brain stimulation remains an effective treatment for Parkinson's

A "brain pacemaker" called deep brain stimulation (DBS) remains an effective treatment for Parkinson's disease for at least three years, according to a study in the June 2010 online issue of Neurology, the medical journal of the American Academy of Neurology.

21 Jun 2012

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they are launching the latest version of their medical device technology for assessing Parkinson’s disease next week at the Movement Disorders Society Congress in Dublin, Ireland.

14 Jun 2012

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

Great Lakes NeuroTechnologies announced today that the U.S. Patent Office has issued claims under patent number 8,187,209 covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders.

6 Jun 2012